The completion of the acquisition of Mibelle Biochemistry by Solabia was announced on July 1, 2026. The transaction, completed with Persán in accordance with the terms announced on February 19, 2026, involves a company specializing in biotechnology-based active ingredients for the health and beauty industries.
Portfolio Focused on Plant Stem Cells
Mibelle Biochemistry, founded in Switzerland in 1991, is recognized for its expertise in PhytoCellTec plant stem cell technology and for its use of modern biotechnologies. Its active ingredients address skin beauty, healthy aging, hair care, and cognitive support, and are distributed in more than 50 countries.
Industrial and Commercial Complementarity
Solabia is combining its international presence and industrial capabilities with Mibelle’s expertise to expand its ingredient portfolio. Jean-Baptiste Dellon, CEO of Solabia, said: «The completion of this acquisition marks a new chapter for Solabia and Mibelle Biochemistry. Our teams share the same commitment to scientific excellence, sustainable innovation, and close collaboration with our customers. Together, we are now even better positioned to support our customers with a broader, stronger, and highly complementary range of ingredients.»
Cornelia Schürch, head of Mibelle Biochemistry, added: «Joining Solabia gives Mibelle Biochemistry the opportunity to build on its strong scientific heritage while opening up new avenues for international growth. We are delighted to combine our expertise with Solabia’s capabilities and to continue offering our customers around the world innovative, high-quality ingredients.»
The transaction is part of Solabia's growth strategy, which aims to strengthen its expertise in natural and biotechnological ingredients for the beauty and wellness markets.
The group now faces its next operational phase, in which it will need to integrate its product portfolios and ensure industrial and commercial rollout on an international scale.
